[Progress in diagnosis and treatment of Crohn disease].
Yao
Tsuneyoshi
T
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D019819:Budesonide / Q000627:therapeutic use; D002352:Carrier Proteins / Q000235:genetics; D003424:Crohn Disease / Q000175:diagnosis* / Q000628:therapy*; D016207:Cytokines / Q000097:blood; D006801:Humans; D000069285:Infliximab; D047908:Intracellular Signaling Peptides and Proteins; D009154:Mutation; D053473:Nod2 Signaling Adaptor Protein; D018529:Nutritional Support; D011239:Prednisolone / Q000008:administration & dosage; D012015:Reference Standards
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D002352:Carrier Proteins; D016207:Cytokines; D047908:Intracellular Signaling Peptides and Proteins; C429018:NOD2 protein, human; D053473:Nod2 Signaling Adaptor Protein; D019819:Budesonide; D011239:Prednisolone; D000069285:Infliximab